Advertisement

Canadian Journal of Public Health

, Volume 107, Issue 1, pp e37–e42 | Cite as

Canadian brain cancer survival rates by tumour type and region: 1992–2008

  • Yan YuanEmail author
  • Qian Shi
  • Maoji Li
  • Chenthila Nagamuthu
  • Ellie Andres
  • Faith G. Davis
Quantitative Research

Abstract

OBJECTIVES: To investigate patterns of survival among brain cancer patients in Canada. METHODS: Canadian Cancer Registry data were obtained for all patients with first-ever primary malignant brain tumours diagnosed between 1992 and 2008 (n = 38,095). Follow-up ended with patient death or December 31, 2008, whichever occurred first. Crude Kaplan–Meier estimates were calculated at one, two and five years post-diagnosis. Cox proportional hazard models were used to obtain adjusted hazard ratios by region for major histology types. A time-specific generalized linear model was used to obtain 5-year survival estimates for specific age group, sex and region for major histology types.

RESULTS: The overall five-year survival rate was 27%. No significant difference in survival rate over time is observed. The highest 5-year survival rate was 65% (95% CI: 62.5%–67.4%) for oligodendrogliomas and the lowest was 4.0% (95% CI: 3.7%–4.3%) for glioblastomas. Compared to Ontario, the adjusted 5-year glioblastoma survival estimates were lower in British Columbia, Alberta and the Prairie provinces (Manitoba and Saskatchewan), while the survival estimates were lower in all other regions for diffuse astrocytoma, and lower in Manitoba and Saskatchewan for anaplastic astrocytomas. Estimates were significantly higher for oligodendrogliomas in Alberta, and for anaplastic oligodendrogliomas in Alberta and Quebec (p < 0.05).

CONCLUSION: These data are consistent with previous literature in observing higher survival rates at younger ages, in female patients and for tumours with mixed oligo components. There is a need to further explore the underlying reasons for the observed variation in survival rates by region in an effort to improve the prognosis of brain cancer in the Canadian patient population.

Key Words

Brain neoplasms survival rate Canada 

Résumé

OBJECTIFS: Étudier les profils de survie des patients atteints d’un cancer du cerveau au Canada.

MÉTHODE: Nous avons obtenu les données du Registre canadien du cancer sur tous les patients atteints d’une première tumeur cérébrale maligne primaire diagnostiquée entre 1992 et 2008 (n = 38 095). Le suivi s’est terminé au décès des patients ou au 31 décembre 2008, selon la première des deux éventualités. Des estimations de Kaplan-Meier brutes ont été calculées à un, deux et cinq ans après le diagnostic. Nous avons utilisé des modèles des risques proportionnels de Cox pour obtenir des coefficients de danger ajustés par région pour les grands types histologiques, respectivement. Un modèle linéaire généralisé dans le temps a servi à obtenir des estimations de survie après 5 ans par groupe d’âge, par sexe et par région pour les grands types histologiques. k ]RÉSULTATS: Le taux de survie global était de 27 %. On n’observe aucun écart significatif dans le taux de survie au fil du temps. Le taux de survie le plus élevé après 5 ans était de 65 % (IC de 95 %: 62,5 %–67,4 %) pour les oligodendrogliomes; le plus faible était de 4 % (IC de 95 %: 3,7 %–4,3 %) pour les glioblastomes. Comparativement à l’Ontario, les estimations ajustées de survie au glioblastome après 5 ans étaient inférieures en Colombie-Britannique, en Alberta et dans les provinces des Prairies (Manitoba et Saskatchewan), tandis que les estimations de survie étaient inférieures dans toutes les autres régions pour les astrocytomes diffus, et inférieures au Manitoba et en Saskatchewan pour les astrocytomes anaplasiques. Les estimations étaient sensiblement plus élevées pour les oligodendrogliomes en Alberta, et pour les oligodendrogliomes anaplasiques en Alberta et au Québec (p < 0,05).

CONCLUSION: Ces données sont conformes à celles d’études antérieures où l’on a observé des taux de survie supérieurs chez les jeunes patients, chez les femmes et pour les tumeurs mixtes (oligo-astrocytomes). Il faudrait pousser la recherche sur les raisons sous-jacentes de la variation observée des taux de survie par région afin d’améliorer le pronostic du cancer du cerveau dans la population de patients au Canada.

Mots Clés

tumeurs du cerveau taux de survie Canada 

References

  1. 1.
    Davis F, Nagamuthu C, Ross J, Megyesi J. Current status of brain tumour surveillance in Canada and why it matters. J Registry Manage 2015;42(4): 139–45. PMID: 26938650.Google Scholar
  2. 2.
    Shaw A, Woods R, Semenciw R, Megyesi J. CNS tumours in Canada: Who are we missing? NAACCR 2014 Annual Conference: Capitalizing on Cancer Surveillance Data for Improved Cancer Control. Ottawa, 2014.Google Scholar
  3. 3.
    Shugg D, Allen BJ, Blizzard L, Dwyer T, Roder D. Brain cancer incidence, mortality and case survival: Observations from two Australian cancer registries. Int J Cancer 1994;59(6):765–70. PMID: 7989116. doi: 10.1002/(ISSN)1097-0215.CrossRefGoogle Scholar
  4. 4.
    Sant M, Van Der Sanden G, Capocaccia R. Survival rates for primary malignant brain tumours in Europe. Eur J Cancer 1998;34(14):2241–47. doi: 10.1016/S0959-8049(98)00336-0.CrossRefGoogle Scholar
  5. 5.
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 1998;88(1):1–10. PMID: 9420066. doi: 10.3171/jns.1998.88.1.0001.CrossRefGoogle Scholar
  6. 6.
    Bray F, Engholm G, Hakulinen T, Gislum M, Tryggvadóttir L, Storm HH, et al. Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol 2010;49(5):673–93. PMID: 20192877. doi: 10.3109/02841861003610200.CrossRefGoogle Scholar
  7. 7.
    Jung K, Yoo H, Kong H, Won Y, Park S, Lee SH. Population-based survival data for brain tumors in Korea. J Neurooncol 2012;109(2):301–07. PMID: 22660961. doi: 10.1007/s11060-012-0893-5.CrossRefGoogle Scholar
  8. 8.
    Mao Y, Desmeules M, Semenciw RM, Hill G, Gaudette L, Wigle DT. Increasing brain cancer rates in Canada. CMAJ 1991;145(12):1583–91. PMID: 1742695.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: A “state of the science” review. Neuro Oncol 2014;16(7):896–913. PMID: 24842956.CrossRefGoogle Scholar
  10. 10.
    Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto, ON: Canadian Cancer Society, 2015.Google Scholar
  11. 11.
    Zhou QM, Zheng Y, Chibnik LB, Karlson EW, Cai T. Assessing incremental value of biomarkers with multi-phase nested case-control studies. Biometrics 2015;71(4):1139–49. PMID: 26195245. doi: 10.1111/biom.12344.CrossRefGoogle Scholar
  12. 12.
    Uno H, Cai T, Tian L, Wei L. Evaluating prediction rules for t-year survivors with censored regression models. J Am Stat Assoc 2007;102(478):527–37. doi: 10.1198/016214507000000149.CrossRefGoogle Scholar
  13. 13.
    R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: The R Foundation for Statistical Computing. 2015. Available at: http://www.R-project.org/ (Accessed May 12, 2016).Google Scholar
  14. 14.
    Ellison LF, Gibbons L. Five-year relative survival from prostate, breast, colorectal and lung cancer. Health Rep 2001;13(1):21–34.Google Scholar
  15. 15.
    Canadian Partnership Against Cancer. Prostate Cancer Control in Canada: A System Performance Spotlight Report. Toronto, ON: CPAC, 2015.Google Scholar
  16. 16.
    Wouters MWJM, Siesling S, Jansen-Landheer ML, Elferink MA, Belderbos J, Coebergh JW, Schramel FM. Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands. Eur J Surg Oncol 2010;36:S83–92. PMID: 20598845. doi: 10.1016/j.ejso.2010.06.020.CrossRefGoogle Scholar
  17. 17.
    Sant M, Minicozzi P, Allemani C, Cirilli C, Federico M, Capocaccia R, et al. Regional inequalities in cancer care persist in Italy and can influence survival. Cancer Epidemiol 2012;36(6):541–47. PMID: 22770694. doi: 10.1016/j.canep. 2012.06.006.CrossRefGoogle Scholar
  18. 18.
    Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. Brain Pathol 2014; 24(5):429–35. PMID: 25345897. doi: 10.1111/bpa.12171.CrossRefGoogle Scholar
  19. 19.
    Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103(9):714–36. PMID: 21454908. doi: 10.1093/jnci/djr077.CrossRefGoogle Scholar
  20. 20.
    Rachet B, Mitry E, Quinn MJ, Cooper N, Coleman MP. Survival from brain tumours in England and Wales up to 2001. Br J Cancer 2008;99(suppl 1): S98–101. PMID: 18813276. doi: 10.1038/sj.bjc.6604603.CrossRefGoogle Scholar
  21. 21.
    Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012;107(1):207–12. PMID: 21984115. doi: 10.1007/s11060-011-0738-7.CrossRefGoogle Scholar
  22. 22.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 2012;14(suppl 5):v1–49. PMID: 23095881. doi: 10.1093/neuonc/nos218.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2016

Authors and Affiliations

  • Yan Yuan
    • 1
    Email author
  • Qian Shi
    • 1
  • Maoji Li
    • 1
  • Chenthila Nagamuthu
    • 1
  • Ellie Andres
    • 1
  • Faith G. Davis
    • 1
  1. 1.School of Public HealthUniversity of AlbertaEdmontonCanada

Personalised recommendations